Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19

ConclusionsAt the current doses, no treatment significantly reduced viral load in the primary analysis. Favipiravir requires further evaluation with consideration of dose escalation. Lopinavir-ritonavir administration was associated with lower plasma favipiravir concentrations. Trial registrationClinicaltrials.gov NCT04499677EudraCT: 2020-002106-68

Source: PLoS Medicine - October 19, 2022 Category: Internal Medicine Authors: David M. Lowe Source Type: research